
Alexion’s Dual-Binding Nanobody Demonstrates Statistically Significant Improvements in Generalized Myasthenia Gravis
Key Takeaways Gefurulimab shows promise in generalized myasthenia gravis (gMG) treatment: Phase III PREVAIL trial results demonstrate statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) …